An electrochemiluminescence assay for analysis of rabies virus glycoprotein content in rabies vaccines

Vaccine

Volumn 31, Issue 33, 2013, Pages 3333-3338

  Smith, Todd G ^a   Ellison, James A ^a   Ma, Xiaoyue ^b   Kuzmina, Natalia ^a   Carson, William C ^a   Rupprecht, Charles E ^c  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Global Alliance for Rabies Control SA Non profit Company   (United States)

Author keywords

Antigenicity; Electrochemiluminescent assay; Glycoprotein; Immunogenicity; Rabies virus; Vaccine

Indexed keywords

DIPLOID CELL VACCINE; EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RABIES VACCINE; VIRUS GLYCOPROTEIN;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ELECTROCHEMILUMINESCENCE ASSAY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABIES VIRUS; VACCINATION;

ANTIGENICITY; ECL; ED(50); EFFECTIVE DOSE; ELECTROCHEMILUMINESCENT; ELECTROCHEMILUMINESCENT ASSAY; G; GLYCOPROTEIN; IM; IMMUNOGENICITY; INTERNATIONAL UNITS; INTRAMUSCULAR; IU; MAB; MESO SCALE DISCOVERY; MONOCLONAL ANTIBODY; MSD; P.I.; POST CHALLENGE OR POST INFECTION; RABIES VIRUS; RABIES VIRUS NEUTRALIZING ANTIBODY; RABV; RAPID FLUORESCENT FOCUS INHIBITION TEST; RFFIT; RVNA; VACCINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; ELECTROCHEMICAL TECHNIQUES; FEMALE; GLYCOPROTEINS; LUMINESCENT MEASUREMENTS; MICE; PROTEIN FOLDING; RABIES; RABIES VACCINES; SENSITIVITY AND SPECIFICITY; VACCINE POTENCY; VIRAL ENVELOPE PROTEINS;

EID: 84879887765     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.081     Document Type: Article

References (37)

1. Tsiang H., Koulakoff A., Bizzini B., Berwald-Netter Y. Neurotropism of rabies virus: an in vitro study. J Neuropathol Exp Neurol 1983, 42(4):439-452.
2. Baloul L., Camelo S., Lafon M. Up-regulation of Fas ligand (FasL) in the central nervous system: a mechanism of immune evasion by rabies virus. J Neurovirol 2004, 10(6):372-382.
3. Horton D., McElhinney L., Marston D., Wood J., Russell C., Lewis N., et al. Quantifying antigenic relationships among the lyssaviruses. J Virol 2010, 84(22):11841-11848.
4. WHO Expert Committee on Biological Standardization Thirty-Seventh Report. WHO Technical Report Series 1987, Geneva World Health Organization.
5. WHO WHO Expert Committee on Rabies: Eighth Report 1992, World Health Organization.
6. Wilbur L., Aubert M. The NIH test for potency. Laboratory techniques in rabies 1996, 360-368. World Health Organization, Geneva. 4th ed. F.X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
7. Barth R., Diderrich G., Weinmann E. NIH test, a problematic method for testing potency of inactivated rabies vaccine. Vaccine 1988, 6(August (4)):369-377.
8. Jivapaisarnpong T., Schofield T., Krause P.R. A vaccine measured with a highly variable assay: rabies. Biologicals 2009, 37(November (6)):412-415. discussion 21-3.
9. Smith T.G., Wu X., Franka R., Rupprecht C.E. Design of future rabies biologics and antiviral drugs. Adv Virus Res 2011, 79:345-363.
10. Fitzgerald E.A., Needy C.F. Use of the single radial immunodiffusion test as a replacement for the NIH mouse potency test for rabies vaccine. Dev Biol Stand 1986, 64:73-79.
11. Ferguson M., Schild G.C. A single-radial-immunodiffusion technique for the assay of rabies glycoprotein antigen: application for potency tests of vaccines against rabies. J Gen Virol 1982, 59(March (Pt 1)):197-201.
12. Atanasiu P., Perrin P., Delagneau J.F. Use of an enzyme immunoassay with protein A for rabies antigen and antibody determination. Dev Biol Stand 1980, 46:207-215.
13. van der Marel P., van Wezel A.L. Quantitative determination of rabies antigen by ELISA. Dev Biol Stand 1981, 50:267-275.
14. Lafon M., Perrin P., Versmisse P., Sureau P. Use of a monoclonal antibody for quantitation of rabies vaccine glycoprotein by enzyme immunoassay. J Biol Stand 1985, 13(October (4)):295-301.
15. Thraenhart O., Ramakrishnan K. Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera. J Biol Stand 1989, 17(October (4)):291-309.
16. Perrin P., Morgeaux S., Sureau P. In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody. Biologicals 1990, 18(October (4)):321-330.
17. Fournier-Caruana J., Poirier B., Haond G., Jallet C., Fuchs F., Tordo N., et al. Inactivated rabies vaccine control and release: use of an ELISA method. Biologicals 2003, 31(March (1)):9-16.
18. Nagarajan T., Reddy G.S., Mohana Subramanian B., Rajalakshmi S., Thiagarajan D., Tordo N., et al. A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture. Biologicals 2006, 34(March (1)):21-27.
19. Jallet C., Jacob Y., Bahloul C., Drings A., Desmezieres E., Tordo N., et al. Chimeric lyssavirus glycoproteins with increased immunological potential. J Virol 1999, 73(January (1)):225-233.
20. Desmezieres E., Maillard A.P., Gaudin Y., Tordo N., Perrin P. Differential stability and fusion activity of Lyssavirus glycoprotein trimers. Virus Res 2003, 91(February (2)):181-187.
21. Sissoeff L., Mousli M., England P., Tuffereau C. Stable trimerization of recombinant rabies virus glycoprotein ectodomain is required for interaction with the p75NTR receptor. J Gen Virol 2005, 86(September (Pt 9)):2543-2552.
22. Mousli M., Turki I., Kharmachi H., Saadi M., Dellagi K. Recombinant single-chain Fv antibody fragment-alkaline phosphatase conjugate: a novel in vitro tool to estimate rabies viral glycoprotein antigen in vaccine manufacture. J Virol Methods 2007, 146(December (1-2)):246-256.
23. Nimmagadda S.V., Aavula S.M., Biradhar N., Rao V.S., Shanmugham R., Chandran D., et al. Recombinant diabody-based immunocapture enzyme-linked immunosorbent assay for quantification of rabies virus glycoprotein. Clin Vaccine Immunol 2010, 17(August (8)):1261-1268.
24. Marissen W.E., Kramer R.A., Rice A., Weldon W.C., Niezgoda M., Faber M., et al. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol 2005, 79(April (8)):4672-4678.
25. Ellison J.A., Johnson S.R., Kuzmina N., Gilbert A., Carson W.C., VerCauteren K.C., et al. Multidisciplinary approach to epizootiology and pathogenesis of bat rabies viruses in the United States. Zoonoses Public Health 2013, 60(February (1)):46-57.
26. Dietzschold B. Techniques for the purification of rabies virus, its subunits and recombinant products. Laboratory techniques in rabies 1996, 175-180. World Health Organization, Geneva. 4th ed. F.X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
27. Smith J.S., Yager P.A., Baer G.M. A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ 1973, 48(May (5)):535-541.
28. Kuzmin I.V., Niezgoda M., Franka R., Agwanda B., Markotter W., Beagley J.C., et al. Lagos bat virus in Kenya. J Clin Microbiol 2008, 46(April (4)):1451-1461.
29. Dean D.J., Abelseth M.K., Atanasiu P. The fluorescent antibody test. Laboratory techniques in rabies 1996, 88-95. World Health Organization, Geneva. 4th ed. F.X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
30. Wunderli P.S., Dreesen D.W., Miller T.J., Baer G.M. The rabies peripheral challenge test: more accurate determination of vaccine potency. Vaccine 2006, 24(November (49-50)):7115-7123.
31. Thompson D.K., Huffman K.M., Kraus W.E., Kraus V.B. Critical appraisal of four IL-6 immunoassays. PLoS ONE 2012, 7(2):e30659.
32. Blackburn G.F., Shah H.P., Kenten J.H., Leland J., Kamin R.A., Link J., et al. Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnostics. Clin Chem 1991, 37(September (9)):1534-1539.
33. Guglielmo-Viret V., Thullier P. Comparison of an electrochemiluminescence assay in plate format over a colorimetric ELISA, for the detection of ricin B chain (RCA-B). J Immunol Methods 2007, 328(December (1-2)):70-78.
34. Katz J. Desorption of porcine parvovirus from aluminum hydroxide adjuvant with subsequent viral immunoassay or hemagglutination assay. Vet Res Commun 1987, 11(1):83-92.
35. Wu X., Smith T.G., Rupprecht C.E. From brain passage to cell adaptation: the road of human rabies vaccine development. Expert Rev Vaccines 2011, 10(November (11)):1597-1608.
36. Zhu D., Huang S., Gebregeorgis E., McClellan H., Dai W., Miller L., et al. Development of a direct alhydrogel formulation immunoassay (DAFIA). J Immunol Methods 2009, 344(May (1)):73-78.
37. Stokes W., McFarland R., Kulpa-Eddy J., Gatewood D., Levis R., Halder M., et al. Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward. Biologicals 2012, 40(September (5)):369-381.